Study to Assess Efficacy and Safety of VIT-2763 in Subjects With Sickle Cell Disease
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy, safety and tolerability of VIT-2763
for the treatment of sickle cell disease. It is a randomised, double-blind,
placebo-controlled, parallel group trial including a 4 week initial treatment period (Part
A), followed by an additional 4-week period (Part B) with either maintenance of the dose
level or a dose step-up. The study also includes a 4-week follow-up period after treatment.